Other Clinical Trial - Lanreotide in the Treatment of Small Bowel Motility

Status Completed

Clinical Trial Summary

This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders. It is similar to a natural hormone somatostatin that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting medication that is given once a month. It is marketed with a trade name "Somatuline Depot". It is given deep subcutaneously (deep within the layers of the skin) in the superior external quadrant of the buttock. Injection site will be alternated on subsequent injections.

Clinical Trial Description

The investigators hypothesize that in patients with small bowel motility disorders, Lanreotide helps in alleviating the symptoms. Lanreotide is an FDA approved medication for management of acromegaly and neuroendocrine tumors, but has never been used for treating small bowel motility disorders. However, Octreotide which is similar to Lanreotide but is a short acting synthetic somatostatin has been used in few research studies. If a patient is interested and qualifies for the study then he/she will be explained about the study and signature will be collected on the consent form. Health and social history will be collected. Blood work, urine analysis, pregnancy test (in women of reproductive age group and have the capability of getting pregnant)) will be performed to make sure that patient qualifies for the study and for follow-up during the treatment. Physical examination, ECG, wireless motility capsule testing and hydrogen breath testing will be performed. Patients will be required to complete a questionnaire regarding their health. The total study duration from the first administration of study drug is 12 weeks. The study medication will be given once a month for 3 months and there is a 1 month follow-up after the last study medication. There will be a screening visit approximately 1 month before the first study drug administration. ;

Study Design

Related Conditions & MeSH terms

Disease
Gastrointestinal Motility Disorder
Intestinal Disease
Intestinal Diseases

Clinical Trial Details

NCT number	NCT03012594
Study type	Interventional
Source	Northwell Health
Contact
Status	Completed
Phase	Phase 2
Start date	May 11, 2017
Completion date	March 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05551052` - CRC Detection Reliable Assessment With Blood
Recruiting	`NCT05194527` - The Detrimental Course of Acute Intestinal Ischemia
Recruiting	`NCT04605627` - The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.
Enrolling by invitation	`NCT04502784` - Investigation of Hypophosphataemia Following Intravenous Iron
Completed	`NCT03559543` - Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma	Phase 2
Completed	`NCT03723447` - Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)	Phase 4
Completed	`NCT04573959` - Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System	N/A
Active, not recruiting	`NCT01236833` - Lactated Ringer's Solution in Neonates With Feeding Intolerance	Phase 2
Not yet recruiting	`NCT04123990` - Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease	N/A
Not yet recruiting	`NCT06271538` - Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome	Phase 4
Completed	`NCT02785783` - Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection	N/A
Recruiting	`NCT06007313` - Mental Stress and Bowel Preparation Quality
Completed	`NCT04982302` - Gut Microbial Changes After Periodontal Treatment
Completed	`NCT03543540` - Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease	Phase 1
Completed	`NCT03817645` - Panaceo "MED" for IBS (Irritable Bowel Syndrome)	N/A
Completed	`NCT00072943` - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease	Phase 2
Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03280407` - NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer	Phase 2
Completed	`NCT04263818` - Endoscopist and Endoscope Motions During Colonoscopy	N/A
Recruiting	`NCT05923918` - A Study to Evaluate Safety and Efficacy of PBK_M2101	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Lanreotide in the Treatment of Small Bowel Motility Disorders

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms